Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 36Neoplasm Metastasis 8Ovarian Neoplasms 5Sarcoma 4Neoplasms 4Lymphoma, Non-Hodgkin 4Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Glioma 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Medulloblastoma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Liposarcoma 2Histiocytosis, Langerhans-Cell 2Hereditary Sensory and Autonomic Neuropathies 2

Interventions

pembrolizumab 12Cisplatin 11Specimen Handling 9Bevacizumab 7Brachytherapy 6Platinum 5Paclitaxel 5Nivolumab 5Magnetic Resonance Spectroscopy 5Human Papillomavirus DNA Tests 5Colposcopy 5Carboplatin 5atezolizumab 4Gemcitabine 4Fulvestrant 4Surveys and Questionnaires 3Radiotherapy 3Radiation Dose Hypofractionation 3Radiation 3Drug Therapy 3Blood Specimen Collection 31,2-diaminocyclohexaneplatinum II citrate 3tisotumab vedotin 2palbociclib 2lenvatinib 2Topotecan 2Restraint, Physical 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × palbociclib × 90 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡